For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $11.21 in the prior trading day, Pliant Therapeutics Inc (NASDAQ: PLRX) closed at $11.07, down -1.25%. In other words, the price has decreased by -$1.25 from its previous closing price. On the day, 0.68 million shares were traded. PLRX stock price reached its highest trading level at $11.3967 during the session, while it also had its lowest trading level at $11.04.
Ratios:
Our goal is to gain a better understanding of PLRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.26 and its Current Ratio is at 10.26. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.17.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $41.
On May 18, 2023, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $48.Canaccord Genuity initiated its Buy rating on May 18, 2023, with a $48 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 10 ’24 when Lefebvre Eric sold 12,319 shares for $11.56 per share. The transaction valued at 142,408 led to the insider holds 213,052 shares of the business.
Hull Hans sold 9,900 shares of PLRX for $114,444 on Jul 10 ’24. The Chief Business Officer now owns 227,494 shares after completing the transaction at $11.56 per share. On Jul 10 ’24, another insider, Cummings Keith Lamont, who serves as the Chief Financial Officer of the company, sold 10,911 shares for $11.56 each. As a result, the insider received 126,131 and left with 282,115 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PLRX now has a Market Capitalization of 682168832 and an Enterprise Value of 329349600.
Stock Price History:
The Beta on a monthly basis for PLRX is 1.05, which has changed by -0.3535179 over the last 52 weeks, in comparison to a change of 0.23171377 over the same period for the S&P500. Over the past 52 weeks, PLRX has reached a high of $18.92, while it has fallen to a 52-week low of $10.22. The 50-Day Moving Average of the stock is -17.63%, while the 200-Day Moving Average is calculated to be -14.52%.
Shares Statistics:
The stock has traded on average 499.91K shares per day over the past 3-months and 415500 shares per day over the last 10 days, according to various share statistics. A total of 60.85M shares are outstanding, with a floating share count of 53.76M. Insiders hold about 11.66% of the company’s shares, while institutions hold 96.27% stake in the company. Shares short for PLRX as of 1735603200 were 7167979 with a Short Ratio of 14.34, compared to 1732838400 on 7242084. Therefore, it implies a Short% of Shares Outstanding of 7167979 and a Short% of Float of 12.0299995.
Earnings Estimates
The current market rating for Pliant Therapeutics Inc (PLRX) reflects the collective analysis of 10.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.98, with high estimates of -$0.86 and low estimates of -$1.1.
Analysts are recommending an EPS of between -$3.57 and -$3.68 for the fiscal current year, implying an average EPS of -$3.63. EPS for the following year is -$3.93, with 11.0 analysts recommending between -$3.11 and -$5.23.
